Buy Crisdesalazine Cas 927685-43-6
Buy Crisdesalazine Cas 927685-43-6
Crisdesalazine (INNTooltip International Nonproprietary Name; developmental code name AAD-2004) is a microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor and free radical scavenger which is under development for the treatment of Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), depressive disorders, Parkinson’s disease, and spinal muscular atrophy.[1][2][3] It was also under development for the treatment of arthritis, diabetes, pain, and pancreatitis, but development for these indications was discontinued.[1] Crisdesalazine is also approved under the brand name GedaCure for treatment of dogs with canine cognitive dysfunction.[4]
Background
The drug was derived from salicylic acids like mesalazine (5-aminosalicylate), aspirin (acetylsalicylate), and sulfasalazine.[2] By inhibiting mPGES-1 (also known as prostaglandin E synthase (PTGES)), it blocks prostaglandin E2 production.[2][5] Crisdesalazine is described as having a dual action, additionally acting as a direct free radical scavenger.[2] Crisdesalazine is described as having anti-inflammatory, antioxidant, and neuroprotective effects.[3] It seems to have potentially superior therapeutic effects compared to nonsteroidal anti-inflammatory drugs (NSAIDs; or cyclooxygenase inhibitors) like ibuprofen, for instance having better selectivity and safety.[2][5]
As of February 2023, crisdesalazine is in phase 1 clinical trials for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), depressive disorders, and Parkinson’s disease and is in the preclinical stage of development for spinal muscular atrophy.[1] It was first described in the scientific literature in 2012.[6][3]
Reviews
There are no reviews yet.